Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall

Neurocrine Biosciences

12/08/2026 14:48

Updates
** Shares of drugmaker Neurocrine Biosciences NBIX.O fall 3.1% to $156.88
** Three organizations issued a joint statement on Tuesday citing post-marketing reports of seven deaths and more than 100 reports of serious adverse events in patients receiving NBIX's drug Vykat XR, which was approved in March 2025
** The drug treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the regulation of gene expression, or how genes turn on and off
** The organizations, however, emphasized that the reports do not establish a causal link between Vykat XR and the adverse outcomes
** Neurocrine added Vykat XR to its portfolio earlier this year through its $2.9 billion acquisition of Soleno Therapeutics
** FDA database shows four deaths related to the drug
** Neurocrine said it is "engaged with the FDA, patient advocacy communities and prescribers to continue to assess all available data from postmarketing surveillance as the prescribing population expands"
** As of last close, stock up 14.2% YTD 

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))